Your fact-checks will appear here
Trade and lobbying group representing American pharmaceutical companies
Available reporting shows large pharmaceutical companies and the industry trade group PhRMA gave sizable donations to Donald Trump’s 2025 inauguration committee — filings and press reports cite indivi...
There is no credible reporting in the provided sources that President Trump “took $100 million from pharma” as a personal payment. The record in these documents shows aggressive White House pressure o...
Claims that “Big Pharma paid Donald Trump $100 million” originate from public remarks by Health Secretary Robert F. Kennedy Jr., who said “I think they gave you $100 million,” about pharmaceutical don...
Bernie Sanders has been accused in high-profile exchanges of taking “Big Pharma” money, but detailed reporting shows those claims misread donor data: OpenSecrets’ industry tallies list Sanders as rece...
Pharmaceutical companies reacted to President Trump’s drug‑pricing campaign with a mix of public pushback, legal resistance to other federal price controls, and selectively cooperative deals that trad...
Campaign finance records and industry studies show pharmaceutical companies and associated PACs gave hundreds of millions to U.S. politics across multiple decades and cycles — for example, OpenSecrets...
Reports show pharmaceutical companies and industry groups gave large inaugural donations to Donald Trump in 2024–25 — individual donations of $1 million from PhRMA and Pfizer are repeatedly cited, and...
Available reporting does not show Trump personally "took $100 million from pharmacy companies." Multiple outlets document that pharmaceutical firms and their trade group (PhRMA) gave large sums to Don...
Available reporting shows pharmaceutical companies, their trade group PhRMA, and pharma executives made measurable payments to Trump-related entities between 2016 and 2025: campaign-cycle contribution...
Open-source tracking groups show that pharmaceutical-sector donations in the 2019–2020 cycle flowed more to Democrats overall than to President Trump, and that individual pharma companies and their em...
Pharmaceutical industry donations and lobbying were a major, organized force in the 2024 healthcare debates, combining tens of millions in direct PAC contributions with hundreds of millions spent on l...
or failure to share individual participant data (IPD) does materially impede scientific verification, secondary analyses, and cumulative knowledge-building, but it does not exist in a vacuum: legitima...
and international requirements for clinical trial data disclosure are a patchwork of statutes, binding regulator rules, and voluntary industry and journal commitments: regulators and companies routine...
OpenSecrets reports that "Pharmaceuticals/Health Products" PACs gave millions to federal candidates in 2023–2024, with industry PAC totals and individual PAC tallies published on its site . However, t...
Public commitments to share de‑identified individual participant data (IPD) exist across the industry — notably the PhRMA/EFPIA pledge effective 1 January 2014 — but audits and reviews show that concr...
OpenSecrets’ industry tallies list Bernie Sanders as receiving roughly $1.42 million from "pharmaceuticals/health products" in the 2020 cycle and about $439,000 in 2016, figures that have been widely ...
OpenSecrets’ industry tallies list Sen. Bernie Sanders as the top Senate recipient from the “pharmaceuticals/health products” category in the 2020 cycle — $1,417,633 — a figure that has been widely qu...
Vaccine trial sponsors typically release high-level documents — trial registrations, protocols or protocol synopses, journal articles and summary results — while retaining detailed regulatory dossiers...
There is no record in the supplied reporting of Robert F. Kennedy Jr. explicitly "admitting" that President Trump accepted money from pharmaceutical lobbyists; what is documented is that major pharmac...
Available reporting shows President Trump and his administration pushed a Most-Favored-Nation (MFN) drug‑pricing campaign in 2025 that produced multiple public deals with major manufacturers and tied ...